ImClone kept at sell by Merrill

ImClone Systems Inc. was maintained at sell by Merrill Lynch analysts Eric J. Ende, David W. Munro and Thomas J. McGahren on news the company announced a partnership with UBC to develop and market CDP-791, a monoclonal antibody for cancer. The analysts said the product deal is not a big value driver. ImClone stock closed up $0.01, or 0.03%, at $32.44 on Tuesday on volume of 1,244,720 shares versus a trailing three-month average of 2,356,970 shares.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.